Sernova Corp. (SVA.TO)
CAD 0.23
(0.0%)
CAD 0.23
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -40.19 Million CAD | -69.33% |
| 2022 | -24.53 Million CAD | -259.71% |
| 2021 | -6.59 Million CAD | -32.09% |
| 2020 | -5.56 Million CAD | -27.83% |
| 2019 | -3.94 Million CAD | -8.14% |
| 2018 | -3.64 Million CAD | -41.77% |
| 2017 | -2.6 Million CAD | -3.47% |
| 2016 | -2.49 Million CAD | -4.55% |
| 2015 | -2.38 Million CAD | -20.03% |
| 2014 | -2.01 Million CAD | -52.43% |
| 2013 | -1.35 Million CAD | 32.95% |
| 2012 | -1.92 Million CAD | -65.59% |
| 2011 | -1.14 Million CAD | -16.9% |
| 2010 | -992.39 Thousand CAD | -51.36% |
| 2009 | -655.66 Thousand CAD | 66.34% |
| 2008 | -2.38 Million CAD | 33.33% |
| 2007 | -2.92 Million CAD | -140.41% |
| 2006 | -1.21 Million CAD | -187.11% |
| 2005 | -423.3 Thousand CAD | 27.74% |
| 2004 | -585.81 Thousand CAD | 16.23% |
| 2003 | -699.33 Thousand CAD | 52.79% |
| 2002 | -1.48 Million CAD | 30.22% |
| 2001 | -2.12 Million CAD | -368.4% |
| 2000 | -453.21 Thousand CAD | -1382.01% |
| 1999 | -30.58 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.98 Million CAD | 16.32% |
| 2024 Q3 | -6.93 Million CAD | 28.91% |
| 2024 Q2 | -9.75 Million CAD | -1.97% |
| 2023 Q4 | -11.39 Million CAD | -16.0% |
| 2023 Q2 | -9.29 Million CAD | -15.62% |
| 2023 Q3 | -9.82 Million CAD | -5.68% |
| 2023 Q1 | -8.04 Million CAD | -1.56% |
| 2023 FY | - CAD | -71.4% |
| 2022 FY | - CAD | -259.71% |
| 2022 Q3 | -5.67 Million CAD | -18.16% |
| 2022 Q1 | -5.34 Million CAD | -126.81% |
| 2022 Q2 | -4.8 Million CAD | 10.14% |
| 2022 Q4 | -7.91 Million CAD | -39.52% |
| 2021 FY | - CAD | -32.09% |
| 2021 Q1 | -1.1 Million CAD | -22.43% |
| 2021 Q3 | -1.55 Million CAD | 2.35% |
| 2021 Q4 | -2.35 Million CAD | -51.79% |
| 2021 Q2 | -1.58 Million CAD | -44.39% |
| 2020 Q2 | -1.67 Million CAD | -26.89% |
| 2020 Q1 | -1.31 Million CAD | 24.58% |
| 2020 Q4 | -899.21 Thousand CAD | 18.52% |
| 2020 Q3 | -1.1 Million CAD | 34.06% |
| 2020 FY | - CAD | -27.83% |
| 2019 Q3 | -861.77 Thousand CAD | -45.02% |
| 2019 Q1 | -702.22 Thousand CAD | 13.79% |
| 2019 FY | - CAD | -8.14% |
| 2019 Q4 | -1.74 Million CAD | -102.95% |
| 2019 Q2 | -594.26 Thousand CAD | 15.37% |
| 2018 Q1 | -743.96 Thousand CAD | 23.12% |
| 2018 FY | - CAD | -41.77% |
| 2018 Q4 | -814.54 Thousand CAD | 25.26% |
| 2018 Q3 | -1.08 Million CAD | -12.84% |
| 2018 Q2 | -965.8 Thousand CAD | -29.82% |
| 2017 Q2 | -656.18 Thousand CAD | -123.04% |
| 2017 Q1 | -294.2 Thousand CAD | -62.52% |
| 2017 FY | - CAD | -3.47% |
| 2017 Q4 | -967.71 Thousand CAD | -53.29% |
| 2017 Q3 | -631.29 Thousand CAD | 3.79% |
| 2016 Q3 | -975.99 Thousand CAD | -51.01% |
| 2016 Q4 | -181.02 Thousand CAD | 81.45% |
| 2016 FY | - CAD | -4.55% |
| 2016 Q1 | -660.56 Thousand CAD | 25.18% |
| 2016 Q2 | -646.3 Thousand CAD | 2.16% |
| 2015 Q4 | -882.91 Thousand CAD | -33.22% |
| 2015 Q2 | -406.98 Thousand CAD | -0.74% |
| 2015 Q3 | -662.72 Thousand CAD | -62.84% |
| 2015 Q1 | -404.01 Thousand CAD | -3.17% |
| 2015 FY | - CAD | -20.03% |
| 2014 Q3 | -616.41 Thousand CAD | -9.18% |
| 2014 FY | - CAD | -52.43% |
| 2014 Q4 | -391.6 Thousand CAD | 36.47% |
| 2014 Q2 | -564.56 Thousand CAD | -37.42% |
| 2014 Q1 | -410.84 Thousand CAD | -34.49% |
| 2013 Q4 | -305.47 Thousand CAD | -40.94% |
| 2013 Q2 | -378.2 Thousand CAD | -2.62% |
| 2013 Q1 | -368.55 Thousand CAD | -66.65% |
| 2013 FY | - CAD | 32.95% |
| 2013 Q3 | -216.73 Thousand CAD | 42.69% |
| 2012 FY | - CAD | -65.59% |
| 2012 Q1 | -406.16 Thousand CAD | -48.47% |
| 2012 Q4 | -221.16 Thousand CAD | 39.39% |
| 2012 Q2 | -543.63 Thousand CAD | -33.85% |
| 2012 Q3 | -364.9 Thousand CAD | 32.88% |
| 2011 Q1 | -314.15 Thousand CAD | -15.56% |
| 2011 FY | - CAD | -16.9% |
| 2011 Q4 | -273.56 Thousand CAD | -24.19% |
| 2011 Q3 | -220.27 Thousand CAD | 37.98% |
| 2011 Q2 | -355.18 Thousand CAD | -13.06% |
| 2010 FY | - CAD | -51.36% |
| 2010 Q2 | -216.12 Thousand CAD | 9.65% |
| 2010 Q3 | -265.23 Thousand CAD | -22.72% |
| 2010 Q4 | -271.84 Thousand CAD | -2.49% |
| 2010 Q1 | -239.19 Thousand CAD | 13.19% |
| 2009 Q2 | -172.42 Thousand CAD | -142.85% |
| 2009 FY | - CAD | 66.34% |
| 2009 Q3 | -132.74 Thousand CAD | 23.01% |
| 2009 Q4 | -275.54 Thousand CAD | -107.58% |
| 2009 Q1 | -71 Thousand CAD | 76.46% |
| 2008 Q1 | -455.47 Thousand CAD | -92.0% |
| 2008 Q4 | -301.58 Thousand CAD | 1.78% |
| 2008 FY | - CAD | 33.33% |
| 2008 Q3 | -307.05 Thousand CAD | 66.35% |
| 2008 Q2 | -912.6 Thousand CAD | -100.36% |
| 2007 Q4 | -237.22 Thousand CAD | 75.63% |
| 2007 Q3 | -973.54 Thousand CAD | 5.47% |
| 2007 Q1 | -334.32 Thousand CAD | -385.64% |
| 2007 Q2 | -1.02 Million CAD | -208.04% |
| 2007 FY | - CAD | -140.41% |
| 2006 Q4 | 117.04 Thousand CAD | 209.19% |
| 2006 FY | - CAD | -187.11% |
| 2006 Q2 | -1.13 Million CAD | -1027.97% |
| 2006 Q3 | -107.19 Thousand CAD | 90.53% |
| 2006 Q1 | -100.3 Thousand CAD | -13.06% |
| 2005 Q1 | -79.95 Thousand CAD | 49.72% |
| 2005 Q2 | -157.46 Thousand CAD | -96.95% |
| 2005 Q3 | -76.63 Thousand CAD | 51.33% |
| 2005 Q4 | -88.71 Thousand CAD | -15.75% |
| 2005 FY | - CAD | 27.74% |
| 2004 FY | - CAD | 16.23% |
| 2004 Q4 | -159.02 Thousand CAD | -67.05% |
| 2004 Q3 | -95.19 Thousand CAD | 38.08% |
| 2004 Q2 | -153.73 Thousand CAD | 13.56% |
| 2004 Q1 | -177.86 Thousand CAD | -88.41% |
| 2003 Q1 | -277.4 Thousand CAD | -16.37% |
| 2003 Q3 | -82.93 Thousand CAD | 66.09% |
| 2003 FY | - CAD | 52.79% |
| 2003 Q4 | -94.4 Thousand CAD | -13.83% |
| 2003 Q2 | -244.59 Thousand CAD | 11.83% |
| 2002 FY | - CAD | 30.22% |
| 2002 Q3 | -321.03 Thousand CAD | 30.73% |
| 2002 Q2 | -463.44 Thousand CAD | -1.09% |
| 2002 Q1 | -458.44 Thousand CAD | 0.0% |
| 2002 Q4 | -238.37 Thousand CAD | 25.75% |
| 2001 FY | - CAD | -368.4% |
| 2000 FY | - CAD | -1382.01% |
| 1999 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Appili Therapeutics Inc. | -2.09 Million CAD | -1817.265% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | -7.481% |
| Helix BioPharma Corp. | -9.38 Million CAD | -328.087% |
| Microbix Biosystems Inc. | 1.95 Million CAD | 2153.745% |
| Medicenna Therapeutics Corp. | -18.67 Million CAD | -115.282% |
| Satellos Bioscience Inc. | -15.7 Million CAD | -155.926% |
| Oncolytics Biotech Inc. | -33.71 Million CAD | -19.232% |